文献速递消化内镜消化道肿瘤与早癌

人工智能辅助结肠镜检测对肿瘤检出率影响的大规模前瞻性倾向评分匹配研究

Impact of the clinical use of artificial intelligence-assisted neoplasia detection for colonoscopy: a large-scale prospective, propensity score-matched study (with video).
PubMed 文献 · Gastrointest Endosc · 2021-08-02

该研究在大学医院开展前瞻性倾向评分匹配分析,纳入接受结肠镜检查的患者,比较使用与不使用计算机辅助检测(CADe)系统的腺瘤检出率(ADR)。倾向评分匹配后共分析1836例患者(每组918例),CADe组ADR显著高于对照组(26.4% vs 19.9%,相对风险1.32,95%CI 1.12-1.57),但进展期肿瘤检出率无显著增加(3.7% vs 2.9%)。

要点

  • CADe系统可显著提高结肠镜腺瘤检出率(26.4% vs 19.9%)。
  • 进展期肿瘤检出率未见显著增加(3.7% vs 2.9%)。
  • 研究涉及30名内镜医师,结果来自大规模前瞻性数据。

核心结论

  • 使用CADe系统进行结肠镜检查可显著提高腺瘤检出率,但未显著增加进展期肿瘤检出率。

研究设计与样本

  • 前瞻性倾向评分匹配研究,在大学医院开展,研究期间为2020年7月至12月。
  • 纳入年龄≥20岁且计划接受结肠镜检查的患者,排除息肉病、炎症性肠病或结肠镜检查不完整的患者。
  • 共2261例患者接受CADe或常规结肠镜检查,排除172例后,经5个因素倾向评分匹配,最终分析1836例(每组918例)。
  • 涉及30名内镜医师(9名非专家和21名专家)。

主要发现

  • CADe组腺瘤检出率为26.4%,对照组为19.9%,相对风险1.32(95%CI 1.12-1.57)。
  • 进展期肿瘤检出率在CADe组为3.7%,对照组为2.9%,无显著增加。

临床怎么用

  • 在临床结肠镜实践中,可考虑使用经监管批准的CADe系统以提高腺瘤检出率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Recently, the use of computer-aided detection (CADe) for colonoscopy has been investigated to improve the adenoma detection rate (ADR). We aimed to assess the efficacy of a regulatory-approved CADe in a large-scale study with high numbers of patients and endoscopists. METHODS: This was a propensity score-matched prospective study that took place at a university hospital between July 2020 and December 2020. We recruited patients aged ≥20 years who were scheduled for colonoscopy. Patients with polyposis, inflammatory bowel disease, or incomplete colonoscopy were excluded. We used a regulatory-approved CADe system and conducted a propensity score matching-based comparison of the ADR between patients examined with and without CADe as the primary outcome. RESULTS: During the study period, 2261 patients underwent colonoscopy with the CADe system or routine colonoscopy, and 172 patients were excluded in accordance with the exclusion criteria. Thirty endoscopists (9 nonexperts and 21 experts) were involved in this study. Propensity score matching was conducted using 5 factors, resulting in 1836 patients included in the analysis (918 patients in each group). The ADR was significantly higher in the CADe group than in the control group (26.4% vs 19.9%, respectively; relative risk, 1.32; 95% confidence interval, 1.12-1.57); however, there was no significant increase in the advanced neoplasia detection rate (3.7% vs 2.9%, respectively). CONCLUSIONS: The use of the CADe system for colonoscopy significantly increased the ADR in a large-scale prospective study including 30 endoscopists (Clinical trial registration number: UMIN000040677.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Ishiyama M, Kudo SE, Misawa M, et al. Impact of the clinical use of artificial intelligence-assisted neoplasia detection for colonoscopy: a large-scale prospective, propensity score-matched study (with video). Gastrointest Endosc. 2021. PMID: 34352255. doi:10.1016/j.gie.2021.07.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。